Navigation Links
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Date:4/8/2008

be used as monotherapy or concomitantly with MTX in pediatric patients. ORENCIA should not be administered concomitantly with TNF antagonists. ORENCIA is not recommended for use concomitantly with other biologic RA therapy, such as anakinra.

For adult patients with RA, ORENCIA, a lyophilized powder for intravenous infusion, should be administered by a healthcare professional as a 30-minute intravenous infusion at a fixed dose based on body weight range approximating 10 mg/kg. Following the initial administration, ORENCIA should be given at two and four weeks after the first infusion and every four weeks thereafter. Acute infusion-related reactions were experienced in nine percent of people treated with ORENCIA and in six percent of people treated with placebo. The most frequently reported infusion-related adverse events (one percent to two percent) were dizziness, headache, and hypertension. In clinical studies, premedications were not required. However, appropriate medical support measure of the treatment of hypersensitivity reactions should be available for immediate use in the event of a reaction.

For pediatric and adolescent patients with JIA who weigh less than 75 kg, ORENCIA(R) (abatacept) should be administered as a 30-minute intravenous infusion at a dose of 10 mg/kg specifically calculated based on the patient's body weight at each administration, not to exceed a maximum dose of 1000 mg. Pediatric patients weighing 75 kg or more should be administered ORENCIA following the adult dosing regimen. Following the initial administration, ORENCIA should be given at two and four weeks after the first infusion and every four weeks thereafter. ORENCIA may be used as monotherapy or concomitantly with MTX.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is a global biopharmaceutical and related health care products company whose mission is to extend and enhance human life.

1 FDA Website. Approval History: sBLA 125057/
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
7. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 /PRNewswire/ ... announced a partnership to expand awareness of proper nutritional ... CFChef Shares program. CFChef Shares will run from August ... CFChef program – an online resource for CF patients ... healthy diet by submitting recipes to the Chef4CF.com ...
(Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
(Date:8/1/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... study evaluating ISIS-SMN Rx in infants with spinal ... infant mortality. Isis plans to dose the first infant ... which time Isis will earn an $18 million milestone ... 3 study, ENDEAR, is the first of several planned ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5
... UNION CITY, Calif., Sept. 9, 2011 Abaxis, Inc. ... analysis systems, announced today that Clint Severson, chairman and ... Annual Best Ideas Conference 2011 on Wednesday, September 14, ... held at The Omni Berkshire Place Hotel in New ...
... Inc. (" Valeant ") (NYSE/TSX:VRX), announced today that Valeant mailed ... ") its offer and take-over bid circular in connection with ... all of the outstanding common shares of Afexa (the " ... per Common Share. The Offer expires at 5:00p.m. ...
Cached Medicine Technology:Abaxis, Inc. to Present at CL King's 9th Annual Best Ideas Conference 2011 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 3Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 4
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... manufacturing jobs may have significantly less endurance than those who weigh ... people -- half were obese, half were of normal weight -- ... 60 percent longer. Obesity also was associated with less strength, ... older -- 50 to 65 years of age -- neither improved ...
(Date:8/1/2014)... Ohio In a first-of-its-kind study, researchers at University ... that lap infants may be at greater risk for ... pediatric medical emergencies on flights worldwide between January 2010 ... occurred in children under the age of 2. ... to characterize the rare event of an in-flight pediatric ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 As AndroGel ... the country, Ronald E. Johnson, Jr. has been appointed ... AndroGel and other testosterone medications. Since the Fall of ... P.S.C. have worked diligently to investigate and prosecute the ... embolisms, and blood clots as a result of taking ...
(Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:New research characterizes in-flight pediatric deaths 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
... , 221.10.254.64 COLUMBIA, Mo. Due to changing ... be screened for breast cancer with mammograms, many women ... years and older get a mammogram every year, but ... other year for women older than 50. A University ...
... to help oncologists keep up to date with the ... been launched by the European Society for Medical Oncology ... and news organization. OncologyPRO Oncology Professional ... -- integrating regularly updated oncology news, clinical research, biomarker ...
... An early phase multiple myeloma trial has unexpectedly ... in cells that affect its dose level in the ... Cancer Center Arthur G. James Cancer Hospital and ... conducted the study., Lenalidomide is an anti-inflammatory drug, and ...
... MONDAY, Aug. 8 (HealthDay News) -- Older patients with ... verbal memory impairment, a new study finds. Verbal ... compared heart failure severity and cognitive function -- including ... for potential heart transplantation. Heart failure severity was ...
... features of the influenza virus,s entry point into human ... flu vaccine to protect against a broad range of ... to develop, produce, and distribute a new vaccine for ... Stephen C. Harrison, PhD, chief of the Division of ...
... new source for sexual problems among middle-aged and older ... men,s closest friends. Cornell University and University of ... and the social networks shared by heterosexual men and ... betweenness." In such cases, a man,s female partner has ...
Cached Medicine News:Health News:Doctors, women should spend more time discussing mammograms 2Health News:OncologyPRO -- a revolutionary resource for oncologists 2Health News:Study urges caution with lenalidomide dosage 2Health News:Fine-tuning the flu vaccine for broader protection 2Health News:When a man's female partner becomes too buddy-buddy with his pals, his sex life may suffer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: